Abstract 4358: Analysis of the cell surface proteome for the identification of candidate diagnostic and therapeutic targets in drug resistant childhood acute lymphoblastic leukemia (ALL)

Beat Bornhäuser(University Children's Hospital Zurich), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Paulina Mirkowska(University of Zurich), Martin Schrappe(University Hospital Schleswig-Holstein), Gunnar Cario, Maike Schmitz(University of Zurich), Andreas Hofmann(ETH Zurich), Bernd Wollscheid(University of Zurich), Martin Stanulla(Leibniz University Hannover)
Cancer Research
April 1, 2010
10.1158/1538-7445.am10-4358
Cited by 0

Related Papers

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
|Blood|2008|607
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
|The Lancet|2002|401
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347